544dbca2-f436-4cb7-9e11-572ead91d28d
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.470
- MYOGENESIS+0.390
- UV_RESPONSE_DN+0.390
- ANGIOGENESIS+0.350
- CHOLESTEROL_HOMEOSTASIS+0.270
- TGF_BETA_SIGNALING+0.270
- WNT_BETA_CATENIN_SIGNALING+0.270
- ESTROGEN_RESPONSE_EARLY+0.240
- APICAL_JUNCTION+0.230
- KRAS_SIGNALING_DN+0.220
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.580
- MYC_TARGETS_V2-0.560
- MYC_TARGETS_V1-0.540
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.490
- ALLOGRAFT_REJECTION-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.420
- DNA_REPAIR-0.410
- E2F_TARGETS-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613703 | — | D | 0.899 |
| 2 | s0122297 | — | — | 0.859 |
| 3 | TCGA-P6-A5OF-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.855 |
| 4 | TCGA-BH-A0W4-01A-11R-A109-07 | — | A | 0.849 |
| 5 | TCGA-56-8626-01A-11R-2403-07 | — | cohortSQ1 | 0.844 |
| 6 | SRR8518453 | — | F | 0.837 |
| 7 | TCGA-HN-A2OB-01A-21R-A27Q-07 | — | A | 0.835 |
| 8 | X8de42096.ef3e.4864.8ee1.2ee7672c1c82 | — | cohortSQ1 | 0.834 |
| 9 | 87fad31a-da7d-4904-93bd-29a7290a316b | — | — | 0.831 |
| 10 | SRR8613781 | — | A | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.470 | Inavolisib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |